GelStat Corp. (OTCMKTS:GSAC – Get Free Report) was the target of a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 323,333 shares, a growth of 9,274.7% from the October 15th total of 3,449 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average trading volume of 9,993,765 shares, the short-interest ratio is currently 0.0 days.
GelStat Price Performance
GelStat stock traded up $0.00 during midday trading on Tuesday, hitting $0.00. 506,898 shares of the stock were exchanged, compared to its average volume of 2,263,588. GelStat has a 52 week low of $0.00 and a 52 week high of $0.00.
About GelStat
GelStat Corporation is a specialty healthcare company associated with the development and marketing of over-the-counter products intended to address common health conditions. The company is best known for GelStat Migraine, a nonprescription product marketed for the temporary relief of migraine-related symptoms. Historically, GelStat’s product portfolio also included other consumer healthcare offerings, including products positioned for sleep support and relief from cold-related symptoms. The company’s approach focused on proprietary formulations and alternative delivery methods designed for direct consumer use rather than prescription-based treatment.
See Also
- Five stocks we like better than GelStat
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for GelStat Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GelStat and related companies with MarketBeat.com's FREE daily email newsletter.
